What is the Richmond Agitation‑Sedation Scale (RASS) and what target RASS range should be maintained for mechanically ventilated patients?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 15, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Richmond Agitation-Sedation Scale (RASS) Overview and Target Range

The Richmond Agitation-Sedation Scale (RASS) is a validated 10-point scale ranging from +4 (combative) to -5 (unarousable), and mechanically ventilated ICU patients should be maintained at a target RASS of -2 to 0 (light sedation) to optimize clinical outcomes. 1

What is RASS?

The RASS is the most valid and reliable sedation assessment tool for measuring quality and depth of sedation in adult ICU patients 1. It demonstrates:

  • Excellent inter-rater reliability (r = 0.956) across diverse ICU clinicians including physicians, nurses, and pharmacists 2
  • High validity with strong correlation (r = 0.93) to visual analog scales and objective measures 2
  • Robust performance across all ICU patient types: medical, surgical, cardiac, neuroscience, ventilated and non-ventilated, sedated and non-sedated 2

RASS Score Definitions

The scale is structured as follows 1:

Agitation levels:

  • +4 to +1: Agitated (combative to restless)
  • 0: Awake and calm

Sedation levels:

  • -1 to -2: Lightly sedated (drowsy, easily arousable)
  • -3 to -5: Deeply sedated (difficult to arouse to unarousable)

Target RASS Range for Mechanically Ventilated Patients

Maintain RASS between -2 and 0 (light sedation range) 1, 3. This target is based on strong evidence showing that lighter sedation levels improve multiple clinical outcomes compared to deep sedation.

Clinical Benefits of Light Sedation (RASS -2 to 0)

The 2013 PAD Guidelines provide Grade 1B recommendation for maintaining light sedation, supported by evidence demonstrating 1:

  • Shorter duration of mechanical ventilation 3, 4
  • Reduced ICU length of stay 1
  • Lower tracheostomy rates 3
  • Improved ability to communicate with patients more arousable and cooperative 4

Practical Implementation Algorithm

Assessment frequency: Monitor RASS at least 4 times per shift and as needed 1

Sedation adjustment protocol 1:

  1. If RASS >0 (under-sedated/agitated):

    • First assess and treat pain
    • Then administer sedatives as needed
    • Prefer non-benzodiazepines (propofol or dexmedetomidine) unless alcohol or benzodiazepine withdrawal suspected

  2. If RASS <-2 (over-sedated):

    • Hold sedatives until patient reaches target range
    • Restart at 50% of previous dose
    • Reassess frequently

  3. If RASS = -2 to 0 (at target):

    • Continue current regimen
    • Monitor regularly for changes

Important Clinical Considerations

Daily sedation interruption (DSI): Either use DSI or titrate sedatives to maintain light levels of sedation (RASS -2 to 0) 1. Both strategies are equally effective when the goal is light sedation 1.

Analgesia-first approach: Always treat pain before sedating 1. The guideline explicitly states "Treat pain first; then sedate" 1.

Delirium monitoring: Light sedation reduces delirium incidence 1. Benzodiazepines increase delirium risk and should be avoided when possible 1.

Common Pitfalls to Avoid

Over-sedation (RASS <-2) is associated with 1:

  • Prolonged mechanical ventilation
  • Increased ICU length of stay
  • Higher delirium rates
  • Worse long-term outcomes

Inconsistent RASS documentation: Studies show only 56.8% of patients had RASS assessed within 1 hour of sedative initiation 5, and only 18.9% achieved their RASS goal in the ED 5. This represents a significant implementation gap requiring systematic protocol adherence.

Using objective monitors as primary tools: Brain function monitors (BIS, PSI) should only be used as adjuncts to RASS, not replacements, except in patients receiving neuromuscular blocking agents 1. The correlation between PSI and RASS is strong (r = 0.822), with a PSI cutoff of 50-52 corresponding to RASS 0 to -3 6, but subjective assessment remains the gold standard.

Special Populations

Neuromuscular blockade: When patients receive paralytics and RASS cannot be assessed, use brain function monitoring (BIS, PSI, etc.) as an adjunct 1.

Sepsis patients: Light sedation strategies show similar outcomes whether using dexmedetomidine or propofol, with no difference in 90-day mortality or delirium-free days 4.

The evidence consistently supports that maintaining lighter levels of sedation (RASS -2 to 0) improves clinical outcomes, and the overall benefits outweigh any theoretical risks 1. This represents a paradigm shift from historical deep sedation practices and requires systematic implementation with nursing education, protocol adherence, and regular monitoring 1.

References

2
Research

The Richmond Agitation-Sedation Scale: validity and reliability in adult intensive care unit patients.

American journal of respiratory and critical care medicine, 2002

Related Questions

How is a patient's treatment plan adjusted based on their Richmond Agitation-Sedation Scale (RASS) score?
A 10‑day postpartum woman presents with dysuria and a urine culture growing mixed microbiota >100,000 CFU/mL; how should this be managed?
What is the appropriate 10‑day antibiotic regimen for a patient undergoing ENT follow‑up after image‑guided fine‑needle aspiration/biopsy, assuming no documented β‑lactam allergy?
In a 10‑month‑old infant with a slightly indented coronal suture, normal fontanelles, and appropriate head growth, what is the appropriate next step in management?
What is the minimum recommended duration of antimicrobial therapy for a deep puncture wound?
What are the possible causes of an elevated International Normalized Ratio (INR) in a patient with left ventricular dysfunction who is on chronic warfarin therapy?
Which test should be performed in a patient with sore throat and fever before prescribing antibiotics?
What is the recommended treatment and dosing for non‑purulent cellulitis in an otherwise healthy adult?
In a female patient with ADHD and depression who recently restarted mixed amphetamine salts extended‑release (Adderall XR) 20 mg and began escitalopram (Lexapro) 10 mg four weeks ago, could a single night terror occurring three weeks after starting the medications be attributable to escitalopram?
Which blood tests should be ordered to rule out inflammatory bowel disease?
What is the recommended management for bacne (acne on the upper back)?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.